Erudio Healtherudio.com
Drug
Savolitinib trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying savolitinib: SANOVO. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 8 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| SANOVO NCT05009836 · Hutchmed | first-line EGFRm+/MET+ locally advanced or metastatic NSCLC | Phase 3 | 97 | 44 | Focused | Nov 13, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| CALYPSO NCT02819596 · Queen Mary University of London DeepView → | metastatic renal cell carcinoma | Phase 2 | Deep | View | |||
| SAVOIR NCT03091192 · AstraZeneca DeepView → | MET-driven papillary renal cell carcinoma | Phase 3 | Deep | View | |||
| PAPMET NCT02761057 · National Cancer Institute (NCI) DeepView → | advanced papillary renal cell carcinoma | Phase 2 | Deep | View | |||
| ORCHARD NCT03944772 · AstraZeneca StandardView → | EGFR-mutated advanced NSCLC after first-line osimertinib | Phase 2 | Standard | View | |||
| SAFFRON NCT05261399 · AstraZeneca FocusedView → | EGFR-mutated, MET-overexpressed/amplified locally advanced or metastatic NSCLC | Phase 3 | Focused | View | |||
| SAVANNAH NCT03778229 · AstraZeneca FocusedView → | EGFR-mutated MET+ advanced NSCLC following progression on osimertinib | Phase 2 | Focused | View | |||
| NCT02897479 NCT02897479 · Hutchison Medipharma Limited FocusedView → | Not given | Phase 2 | Focused | View | |||
| SAMETA NCT05043090 · AstraZeneca FocusedView → | MET-driven unresectable locally advanced/metastatic papillary renal cell carcinoma | Phase 3 | Focused | View | |||